@article{0c6423e5a5294e76a6ce91206b91f372,
title = "The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response",
abstract = "The therapeutic landscape of drugs targeting the DNA damage response (DDR) is rapidly expanding; however, an urgent unmet need remains for validated predictive biomarkers of response. SLFN11 has emerged as a promising predictor of sensitivity to DNA-damaging chemotherapies, and recently, been associated with sensitivity to PARP inhibition. We discuss its use as a predictive biomarker of response for targeting the DDR.",
author = "Niamh Coleman and Bingnan Zhang and Byers, {Lauren A.} and Yap, {Timothy A.}",
note = "Funding Information: Funding information The authors acknowledge the MD Anderson Cancer Center support grant (P30 CA016672). T.A.Y. is a V Foundation V Clinical Scholar (VC2020-001), which supports a Program of Clinical Trials targeting the DNA damage response (DDR). Funding Information: Competing interests N.C. and B.Z. declare no competing interests. L.A.B. has received research funding from AstraZeneca, GenMab, Sierra Oncology and ToleroPharmaceu-ticals, and has served as an advisor/consultant for AstraZeneca, GenMab, Sierra Oncology, PharmaMar, AbbVie, Bristol-Myers Squibb, Alethia, Merck, Pfizer and Jazz Pharmaceuticals. T.A.Y. has received research support to the institution from Artios, AstraZeneca, Bayer, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Merck, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Sanofi, Scholar Rock, Seattle Genetics, Tesaro and Vertex Pharmaceuticalsre, and has served as a consultant for Almac, Aduro, AstraZeneca, Atrin, Axiom, Bayer, Bristol-Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, Guidepoint, Ignyta, I-Mab, Jansen, Merck, Pfizer, Repare, Roche, Rubius, Schrodinger, Seattle Genetics, Varian and Zai Labs. Publisher Copyright: {\textcopyright} 2020, Cancer Research UK.",
year = "2021",
month = mar,
day = "2",
doi = "10.1038/s41416-020-01202-y",
language = "English (US)",
volume = "124",
pages = "857--859",
journal = "British journal of cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",
}